In 2021, market growth is set to surpass expectations as the number of active patients approaches 100,000. By year’s end, revenue from product sales is projected to reach $230 million. Although the product count keeps rising, the growth rate of new products is decelerating. Meanwhile, the average monthly spend maintains its gradual decline, while the average daily dose increases.
